Figure 2. Glycolysis. Low dose of MTX caused fluctuation in the biochemicals involved in glycolysis. Biochemicals prior to phosphofructokinase 1 (PFK1) activity showed an upward trend while those downstream showed a downward trend indicative of an inhibition of glycolysis. However, these trends were absent with higher dose of MTX. Infliximab did not elicit much change in the biochemicals involved in glycolysis. The effect of MTX and infliximab exposure for 24 h is shown on glycolytic metabolites: glucose (A), glucose-6-phosphate (B), fructose-6-phosphate (C), fructose 1,6 diphosphate (D), dihydroxyacetone phosphate (E), 3-phosphoglycerate (F), phosphoenolpyruvate (G), lactate (H). See Figure 1 for legend code.